Hematopoietic Engraftment and Survival in Adult Recipients of Umbilical-Cord Blood from Unrelated Donors

Laughlin, Mary J.; Barker, Juliet N.; Bambach, Barbara; Koç, Omer N.; Rizzieri, David A.; Wagner, John E.; Gerson, Stanton L.; Lazarus, Hillard M.; Cairo, Mitchell S.; Stevens, Cladd E.; Rubinstein, Pablo; Kurtzberg, Joanne

doi:10.1056/nejm200106143442402

Cited by 830 publications

(340 citation statements)

References 32 publications

Supporting

Mentioning

324

Contrasting

Unclassified

Order By: Relevance

“…Umbilical cord blood offers advantages over bone marrow because cord blood does not require perfect human leukocyte antigen (HLA) tissue matching, has less incidence of graft vs host disease, and may be used allogenically (11,12). In addition, cord blood may be banked, and thus is available for use "off-the-shelf."…”

Section: Sources Of Stem Cells For Therapeutic Usementioning

confidence: 99%

“…This work suggests that MSCs from a variety of sources, including umbilical cord, may facilitate engraftment of hematopoietic stem cells. This addresses two significant problems found in umbilical cord blood transplantation: (1) getting enough cells to engraft an adult and (2) increasing the speed of engraftment (12,73). Theoretically, cografting or ex vivo expansion may enable transplantation of cord blood units into larger patients and speed the engraftment in other patients.…”

Section: Mscs Support Expansion Of Other Stem Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Stem cells in the umbilical cord

2006

View full text Add to dashboard Cite

Stem cells are the next frontier in medicine. Stem cells are thought to have great therapeutic and biotechnological potential. This will not only to replace damaged or dysfunctional cells, but also rescue them and/or deliver therapeutic proteins after they have been engineered to do so. Currently, ethical and scientific issues surround both embryonic and fetal stem cells and hinder their widespread implementation. In contrast, stem cells recovered postnatally from the umbilical cord, including the umbilical cord blood cells, amnion/placenta, umbilical cord vein, or umbilical cord matrix cells, are a readily available and inexpensive source of cells that are capable of forming many different cell types (i.e., they are "multipotent"). This review will focus on the umbilical cord-derived stem cells and compare those cells with adult bone marrow-derived mesenchymal stem cells.

show abstract

Section: Sources Of Stem Cells For Therapeutic Usementioning

confidence: 99%

Section: Mscs Support Expansion Of Other Stem Cellsmentioning

confidence: 99%

Stem cells in the umbilical cord

2006

View full text Add to dashboard Cite

show abstract

“…C ord blood (CB) is a viable alternative to bone marrow for related and unrelated allogeneic hematopoietic stem cell (HSC)͞progenitor cell (HPC) transplantation (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13). Since our initial preclinical (14)(15)(16) and clinical (1,(17)(18)(19) studies, there have been Ͼ2,000 CB transplants performed to treat a variety of malignant and nonmalignant disorders in children and adults (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(17)(18)(19).…”

mentioning

confidence: 99%

“…Since our initial preclinical (14)(15)(16) and clinical (1,(17)(18)(19) studies, there have been Ͼ2,000 CB transplants performed to treat a variety of malignant and nonmalignant disorders in children and adults (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(17)(18)(19). CB HSC͞HPC are frozen before use for transplantation (14,(20)(21)(22), but the longest that a CB collection has been stored frozen before use for clinical transplantation is in the 3-to 5-yr range.…”

mentioning

confidence: 99%

High-efficiency recovery of functional hematopoietic progenitor and stem cells from human cord blood cryopreserved for 15 years

Broxmeyer

Srour

Hangoc

et al. 2003

Proc. Natl. Acad. Sci. U.S.A.

218

145

View full text Add to dashboard Cite

Transplanted cord blood (CB) hematopoietic stem cells (HSC) and progenitor cells (HPC) can treat malignant and nonmalignant disorders. Because long-term cryopreservation is critical for CB banking and transplantation, we assessed the efficiency of recovery of viable HSC͞HPC from individual CBs stored frozen for 15 yr. Average recoveries (؎ 1 SD) of defrosted nucleated cells, colony-forming unitgranulocyte, -macrophage (CFU-GM), burst-forming unit-erythroid (BFU-E), and colony-forming unit-granulocyte, -erythrocyte, -monocyte, and -megakaryocyte (CFU-GEMM) were, respectively, 83 ؎ 12, 95 ؎ 16, 84 ؎ 25, and 85 ؎ 25 using the same culture conditions as for prefreeze samples. Proliferative capacities of CFU-GM, BFU-E, and CFU-GEMM were intact as colonies generated respectively contained up to 22,500, 182,500, and 292,500 cells. Self-renewal of CFU-GEMM was also retained as replating efficiency of single CFU-GEMM colonies into 2°dishes was >96% and yielded 2°colonies of CFU-GM, BFU-E, and CFU-GEMM. Moreover, CD34 ؉ CD38 ؊ cells isolated by FACS after thawing yielded >250-fold ex vivo expansion of HPC. To assess HSC capability, defrosts from single collections were bead-separated into CD34 ؉ cells and infused into sublethally irradiated nonobese diabetic (NOD)͞severe combined immunodeficient (SCID) mice. CD45 ؉ human cell engraftment with multilineage phenotypes was detected in mice after 11-13 wk; engrafting levels were comparable to that reported with fresh CB. Thus, immature human CB cells with high proliferative, replating, ex vivo expansion and mouse NOD͞SCID engrafting ability can be stored frozen for >15 yr, can be efficiently retrieved, and most likely remain effective for clinical transplantation.C ord blood (CB) is a viable alternative to bone marrow for related and unrelated allogeneic hematopoietic stem cell (HSC)͞progenitor cell (HPC) transplantation (1-13). Since our initial preclinical (14-16) and clinical (1, 17-19) studies, there have been Ͼ2,000 CB transplants performed to treat a variety of malignant and nonmalignant disorders in children and adults (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(17)(18)(19). CB HSC͞HPC are frozen before use for transplantation (14,(20)(21)(22), but the longest that a CB collection has been stored frozen before use for clinical transplantation is in the 3-to 5-yr range. With Ͼ100,000 CBs stored frozen world-wide for prolonged periods in anticipation of their clinical use, information on longer-term storage of CB HSC and HPC is of critical importance.The capacity to freeze and retrieve CB HPC cells was first reported when we suggested that CB could serve as a source of transplantable and engrafting HSC and HPC (14). We subsequently evaluated effects of 5-yr (16) and 10-yr (23) storage on retrieval of HPC in which postfreeze HPC numbers were compared directly to prefreeze numbers from the exact same CB samples. Thus, a true recovery rate could be calculated. At those times, we assessed only numbers and proliferation of HPC in vitro. In the present report, we extended anal...

show abstract

“…Human umbilical cord blood (HUCB) has been used to treat children with various hematological malignant and nonmalignant diseases (Sirchia and Rebulla, 1999). More than six thousand HUCB transplantations have been performed worldwide (Laughlin et al, 2001;Tse and Laughlin, 2005;Wagner et al, 1992), since HUCB was first used to successfully treat a 5-year-old child suffering from Fanconi anemia in 1988 (Gluckman et al, 1989). Recently, a number of reports reveal the many advantages of HUCB cells for cellular therapies, especially compared to bone marrow (BM) stem cells.…”

Section: Introductionmentioning

confidence: 99%